Every 10-Q that Erasca, Inc. (ERAS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ERAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERAS filings page.
Erasca, Inc. reported a larger net loss while significantly strengthening its balance sheet and advancing its RAS/MAPK oncology pipeline for the quarter ended June 30, 2026. Net loss was $44.1 million for the quarter and $227.5 million for the first six months of 2026, compared with $33.9 million and $64.8 million in the prior-year periods, driven largely by a $150.0 million in‑process R&D charge to expand territorial rights under the Joyo pan‑RAS license.
Total assets were $435.1 million, including $384.3 million in cash, cash equivalents, and marketable securities. A January 2026 underwritten offering provided $242.7 million in net proceeds, and a subsequent July 2026 offering added $593.5 million, which management believes will fund operations for at least one year from issuance of these statements.
The company is focusing on ERAS-0015, a pan‑RAS molecular glue, and ERAS-4001, a pan‑KRAS inhibitor. Preliminary Phase 1 data for ERAS‑0015 showed encouraging response rates in KRAS G12X non‑small‑cell lung cancer and pancreatic adenocarcinoma with a generally manageable safety profile, while development of naporafenib under the Novartis agreement has been discontinued.
Erasca, Inc. reported first‑quarter 2026 results marked by a much larger net loss as it doubled down on its RAS/MAPK cancer franchise. Net loss widened to $183.4 million, or $0.60 per share, from $31.0 million a year earlier, mainly due to recording $150.0 million of in‑process research and development expense for expanding territorial rights under its Joyo pan‑RAS license.
Research and development spending excluding that item was $27.3 million, with $13.8 million for ERAS‑0015 and $6.7 million for ERAS‑4001, while general and administrative expense was $10.6 million. A January 2026 underwritten equity offering generated net proceeds of $242.7 million, helping lift total cash, cash equivalents, and marketable securities to $408.5 million and total assets to $461.2 million. The company now expects this liquidity to fund operations into the second half of 2028.
Erasca continues to advance ERAS‑0015 and ERAS‑4001 through early‑stage trials and has stopped development of naporafenib, terminating its Novartis license effective June 3, 2026. Management reiterates that product revenue is not expected for several years, and future funding will likely continue to rely on capital markets and partnering.
Erasca reported total assets of $445.4 million and stockholders' equity of $372.3 million at June 30, 2025. The company held $386.7 million of combined cash, cash equivalents and marketable securities, and had an accumulated deficit of $832.5 million. The company states its cash and marketable securities are expected to fund operations for at least one year from issuance of these financial statements.
For the six months ended June 30, 2025 Erasca recorded a net loss of $64.8 million ($0.23 per share) and a net loss of $33.9 million for the quarter ended June 30, 2025 ($0.12 per share). Key program and corporate items disclosed include IND clearances in May 2025 for ERAS-0015 (AURORAS-1) and ERAS-4001 (BOREALIS-1), the in-license of naporafenib from Novartis, a strategic reprioritization to focus on naporafenib, ERAS-0015 and ERAS-4001, a $7.5 million IPR&D milestone expense related to the Joyo agreement in the period, and a subsequent Amended and Restated ATM agreement dated August 12, 2025 for up to $200 million.